Here's how i think about it.
Current market cap is $285mn.
Scott previously from 51Cap suggested the MPS asset could be worth up to $1bn as a deal and $10bn for full asset. This no doubt includes all lysosomal diseases. Who knows if these numbers are reasonable.
So if they can land a deal for MPS (with good trial results) above $285mn, in a way you have a free option on KOA. The company becomes MASSIVELY derisked.
What's the KOA asset worth- $4-$5+bn U.S.? Probably going to be another 2 years before we find that out.
So I want to see that MPS asset value realised in next 9-12 months.
I expect to see weakness in share price due to tax loss selling like last year and may top up then.
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-368
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 130186 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 11571 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |